1.Hepcidin as a Biomarker of Cardiorenal Syndrome
Journal of Korean Medical Science 2020;35(1):20-
No abstract available.
Cardio-Renal Syndrome
;
Hepcidins
3.Characteristics and Survival of Dialysis Patients due to Type 2 Cardiorenal Syndrome.
Seong CHO ; Sung Rok KIM ; Yu Ji LEE
Korean Journal of Nephrology 2011;30(6):614-621
PURPOSE: We evaluated clinical outcomes in patients with type 2 cardiorenal syndrome who were treated with peritoneal dialysis (PD) or hemodialysis (HD). METHODS: A retrospective database of PD or HD patients with type 2 cardiorenal syndrome from January 1, 2002 to December 31, 2010 was established. We evaluated the mean survival on dialysis, days of hospitalizations and NYHA class changes. RESULTS: Thirty-two patients with mean age at the start of dialysis of 68.4+/-10.8 years had mean survival on dialysis of 20.5+/-14.4 months (median survival 17.8 months). Survival after starting dialysis is highly variable, but long term survival was proved possible. The days of hospitalization for cardiovascular causes were reduced (25.1+/-17.7, predialysis vs. 9.5+/-32.8 days/patient/month, postdialysis, p=0.013). All patients showed improvement in NYHA functional class. Kidney function stabilized, while significant improvement in hemoglobin (+16.5%, p<0.001) were achieved. CONCLUSION: After starting dialysis for Type 2 cardiorenal syndrome, the chances of hospitalization for cardiovascular causes were reduced for all patients. Survival on dialysis in these patients was highly variable.
Cardio-Renal Syndrome
;
Dialysis
;
Hemoglobins
;
Hospitalization
;
Humans
;
Kidney
;
Peritoneal Dialysis
;
Renal Dialysis
;
Retrospective Studies
4.Cardiorenal syndrome: pathophysiological mechanism, preclinical models, novel contributors and potential therapies.
Qiang FU ; Longxing CAO ; Huang LI ; Binghui WANG ; Zhiliang LI
Chinese Medical Journal 2014;127(16):3011-3018
OBJECTIVETo review the current knowledge about the pathophysiological mechanisms, preclinical models, novel contributors and potential therapies of cardiorenal syndrome.
DATA SOURCESThe literature concerning cardiorenal syndrome in this review was collected from PubMed published in English up to January 2014.
STUDY SELECTIONOriginal articles and critical reviews related to cardiorenal syndrome were selected and carefully analyzed.
RESULTSCardiorenal syndrome is a condition characterized by kidney and heart failure where failure of one organ worsens the function of the other thus further accelerating the progressive failure of both organs. The pathophysiology of cardiorenal syndrome is not fully understood, but may be caused by a complex combination of neurohormonal system activation, endothelial dysfunction, proteinuria, oxidative stress, uremic toxins and other factors. Managing cardiorenal syndrome is still a major therapeutic challenge in clinical practice because many of the drugs used to control heart failure can worsen renal function, and vice versa. Non-dialyzable uremic toxins, such as indoxyl sulfate, causing detrimental effects on the heart and kidney as well as stimulation of inflammatory responses, may be an effective therapeutic target for cardiorenal syndrome.
CONCLUSIONSSuitable disease models of cardiorenal syndrome are urgently needed to investigate the pathophysiology and effective therapeutic approaches to the condition. Non-dialyzable protein-bound uremic toxins that may have cardiac and renal effects may provide therapeutic benefit to cardiorenal syndrome patients.
Cardio-Renal Syndrome ; metabolism ; physiopathology ; Female ; Humans ; Male ; Toxins, Biological ; metabolism
5.Renal Dysfunction in Acute Heart Failure.
Korean Circulation Journal 2011;41(10):565-574
During treatment of acute heart failure (AHF), worsening renal function is often complicated and results in a complex clinical course. Furthermore, renal dysfunction is a strong independent predictor of long-term adverse outcomes in patients with AHF. Traditionally, the predominant cause of renal dysfunction has been attributed to impairment of cardiac output and relative underfilling of arterial perfusion. Recently, emerging data have led to the importance of venous congestion and elevated intra-abdominal pressure rather than confining it to impaired forward cardiac output as the primary driver of renal impairment. Relief of congestion is a major objective of AHF treatment but therapy is still based on the administration of loop diuretics. The results of the recently performed controlled studies for the assessment of new treatments to overcome resistance to diuretic treatment to protect kidneys from untoward effects have been mostly neutral. Better treatment of congestion in heart failure remains a major problem.
Cardiac Output
;
Cardio-Renal Syndrome
;
Estrogens, Conjugated (USP)
;
Heart
;
Heart Failure
;
Humans
;
Hyperemia
;
Kidney
;
Perfusion
;
Sodium Potassium Chloride Symporter Inhibitors
6.Connotation of Shenqi Pills based on severe cases in cardiovascular care unit and modern pathophysiological mechanism and application of Shenqi Pills for heart failure, renal failure, cardiorenal syndrome, and diuretic resistance in critical care medicine.
China Journal of Chinese Materia Medica 2023;48(10):2565-2582
Shenqi Pills, first recorded in Essentials from the Golden Cabinet(Jin Kui Yao Lue) from ZHANG Zhong-jing in Han dynasty, have the effect of warming and tonifying the kidney Qi and are mainly used for the treatment of insufficiency of kidney Qi and kidney Yang. According to modern medicine, kidney Qi involves heart function, kidney function, immune function, and so on. The clinical indications of Shenqi Pills include kidney deficiency, abnormal fluid, and abnormal urination, and the last one is classified into little urine, much urine, and dysuria. In clinical settings, Shenqi Pills can be applied for the treatment of heart failure, renal failure, cardiorenal syndrome, and diuretic resistance, as well as endocrine, urological, orthopedic, and other chronic degenerative diseases. Shenqi Pills are ideal prescriptions for the weak constitution and emergency treatment. It is of great value and significance to carry out in-depth research on the connotation of the classic articles by integrating TCM and western medicine based on "pathogenesis combined with pathology and drug properties combined with pharmacology".
Humans
;
Cardio-Renal Syndrome/drug therapy*
;
Diuretics/therapeutic use*
;
Drugs, Chinese Herbal/therapeutic use*
;
Heart Failure/drug therapy*
;
Critical Care
7.Association between lipoprotein (a) level and chronic cardio-renal syndrome in elderly patients.
Yan WANG ; Qiu Yan WANG ; Chang GUAN ; Xin ZHANG ; Yi Fang GUO
Chinese Journal of Cardiology 2020;48(12):1047-1052
Objective: To explore the relationship between lipoprotein(a) [Lp(a)] and chronic cardio-renal syndrome (CRS) in elderly patients. Methods: Chronic heart failure (CHF) patients age ≥ 65 years old, who hospitalized in the department of Cardiology of Hebei General Hospital from December 2017 to October 2019, were included in this study. According to the estimate glomerular filtration rate (eGFR) level, patients were divided into CRS group (eGFR<60 ml·min-1·1.73 m-2) and CHF group (eGFR ≥60 ml·min-1·1.73 m-2). The blood index and basic disease information were collected and compared. Left ventricular ejection fraction (LVEF) were measured by echocardiography. The correlation between clinical indicators and cardio-renal function (LVEF and eGFR) was assessed. The multivariate logistic regression analysis was used to evaluate the related risk factors of CRS in elderly patients; subgroup logistic regression analysis was performed according to the basic disease of patients to assess the relationship between Lp(a) and CRS. Results: A total of 172 elderly patients (85 males (49.4%), aged 79 (71, 84) years) were finally enrolled. Among them, 88 cases (51.2%) were in CRS group and 84 cases (48.8%) were in CHF group. Age (80 (74, 84) years old vs. 74 (70, 82) years old) and LP (a) levels (222.0 (112.0, 445.3) mg/L vs. 155.0 (97.0, 348.7) mg/L) were significantly higher in the CRS group than in the CHF group (P<0.05). Lp(a) levels were negatively correlated with LVEF (r=-0.155, P=0.043) and eGFR (r=-0.220, P=0.004) in total cohort. In the subgroup analysis of patients with 2 high-incidence basic diseases (coronary heart disease and hypertension), Lp(a) was negatively correlated with LVEF (r=-0.250, P=0.007) in the coronary heart disease group, and negatively correlated with eGFR (r=-0.233, P=0.013) in the hypertension group. Multivariate logistic regression analysis showed that age (OR = 1.069, 95%CI: 1.017-1.124, P= 0.009) and Lp(a) (OR = 3.719, 95%CI: 1.339-10.326, P = 0.012) were independent correlates of CRS. The results of logistic regression analysis showed that Lp(a) was an independent correlative factor of CRS in the subgroups of coronary heart disease (OR=3.207, 95%CI: 1.129-9.108, P=0.029) and hypertension (OR=3.054, 95%CI: 1.086-8.587, P=0.034). Conclusion: Serum Lp(a) level is independently related with CRS in elderly patients.
Aged
;
Aged, 80 and over
;
Cardio-Renal Syndrome
;
Heart Failure
;
Humans
;
Lipoprotein(a)
;
Male
;
Prognosis
;
Stroke Volume
;
Ventricular Function, Left
8.Pharmacologic Management of the Cardio-renal Syndrome.
Electrolytes & Blood Pressure 2013;11(1):17-23
Cardio-renal syndromes are disorders of the heart and kidney wherein acute or long-term dysfunction in one organ may induce acute or long-term dysfunction of the other. Because of this complex organ interaction, management of cardiorenal syndrome must be tailored to the underlying pathophysiology. Clinical guidelines exist for the treatment of heart failure or renal failure as separate conditions. Thus far, however, there has been no consensus about managing patients with cardio-renal and reno-cardiac syndromes. Pharmacologic treatment remains a controversial subject. Standard cardiac drugs such as diuretics and inotropes may have limited effect because resistance often develops after long-term use. Recent studies of patients with acute cardio-renal syndromes have focused on newer therapies, including phosphodiesterase inhibitors, vasopressin antagonists, adenosine A1 receptor antagonists, and renal protective dopamine. Initial clinical trials of these agents have shown encouraging results in some patients with heart failure, but have failed to demonstrate a clear superiority over more conventional treatments. Similarly, the benefits of diuretics, aspirin, erythropoietin agents, and iron supplements for management of chronic cardiorenal syndromes are unknown.
Adenosine A1 Receptor Antagonists
;
Aspirin
;
Cardio-Renal Syndrome
;
Consensus
;
Diuretics
;
Dopamine
;
Erythropoietin
;
Heart
;
Heart Failure
;
Humans
;
Iron
;
Kidney
;
Phosphodiesterase Inhibitors
;
Renal Insufficiency
;
Vasopressins
9.Cardiorenal syndrome and vitamin D receptor activation in chronic kidney disease.
Sirous DARABIAN ; Manoch RATTANASOMPATTIKUL ; Parta HATAMIZADEH ; Suphamai BUNNAPRADIST ; Matthew J BUDOFF ; Csaba P KOVESDY ; Kamyar KALANTAR-ZADEH
Kidney Research and Clinical Practice 2012;31(1):12-25
Cardiorenal syndrome (CRS) refers to a constellation of conditions whereby heart and kidney diseases are pathophysiologically connected. For clinical purposes, it would be more appropriate to emphasize the pathophysiological pathways to classify CRS into: (1) hemodynamic, (2) atherosclerotic, (3) uremic, (4) neurohumoral, (5) anemic??hematologic, (6) inflammatory-oxidative, (7) vitamin D receptor (VDR) and/or FGF23-, and (8) multifactorial CRS. In recent years, there have been a preponderance data indicating that vitamin D and VDR play an important role in the combination of renal and cardiac diseases. This review focuses on some important findings about VDR activation and its role in CRS, which exists frequently in chronic kidney disease patients and is a main cause of morbidity and mortality. Pathophysiological pathways related to suboptimal or defective VDR activation may play a role in causing or aggravating CRS. VDR activation using newer agents including vitamin D mimetics (such as paricalcitol and maxacalcitol) are promising agents, which may be related to their selectivity in activating VDR by means of attracting different post-D-complex cofactors. Some, but not all, studies have confirmed the survival advantages of D-mimetics as compared to non-selective VDR activators. Higher doses of D-mimetic per unit of parathyroid hormone (paricalcitol to parathyroid hormone ratio) is associated with greater survival, and the survival advantages of African American dialysis patients could be explained by higher doses of paricalcitol (>10 microg/week). More studies are needed to verify these data and to explore additional avenues for CRS management via modulating VDR pathway.
Cardio-Renal Syndrome
;
Dialysis
;
Ergocalciferols
;
Heart
;
Heart Diseases
;
Hemodynamics
;
Humans
;
Kidney Diseases
;
Parathyroid Hormone
;
Receptors, Calcitriol
;
Renal Insufficiency, Chronic
;
Vitamin D
;
Vitamins
10.Novel Biomarkers for Cardio-renal Syndrome.
Electrolytes & Blood Pressure 2012;10(1):12-17
Cardio-renal syndrome (CRS) is a frequent and life-threatening syndrome. It is a disorder of the heart and kidneys in which acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in the other organ. Acute kidney injury (AKI) is strongly associated with increased morbidity and mortality in patients with CRS. Early detection of renal dysfunction is not possible using the traditional marker, serum creatinine, and therefore efforts to explore possible biomarkers for early detection of AKI are being made. Apart from predicting AKI, several biomarker studies also identified predictors for poor prognosis such as the need for renal replacement therapy (RRT) or death. It is possible that biomarkers can become risk factors in an improvement of clinical outcomes of CRS. Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with renal dysfunction and the treatment for this disease can be modified based on cardiac biomarkers. In addition to natriuretic peptides, which are established cardiac markers, several new biomarkers have been identified and may play important roles in CRS. In this review, we will briefly summarize the literature on novel renal and cardiac biomarkers and discuss their potential roles in the clinical outcome of CRS.
Acute Kidney Injury
;
Cardio-Renal Syndrome
;
Cardiovascular Diseases
;
Creatinine
;
Heart
;
Heart Failure
;
Humans
;
Kidney
;
Natriuretic Peptides
;
Prognosis
;
Renal Replacement Therapy
;
Risk Factors
;
Biomarkers